Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has achieved significant progress in its AI-driven programme for respiratory syncytial virus (RSV) with the successful identification and prioritisation of promising drug candidates, marking a milestone in the application of artificial intelligence in drug discovery.
The team of scientific experts at Poolbeg Pharma evaluated the data from this analysis, strategically selecting a number of RSV drug candidates for further development.
This move is part of the company's broader effort to maximise the value of its research, underscoring its commitment to pioneering AI-led pharmaceutical advancements.
This development is particularly noteworthy given the increasing global interest in AI-assisted drug discovery, a field that is attracting significant investment from major pharmaceutical companies.
Poolbeg Pharma's RSV AI program has demonstrated its potential by identifying these drug treatment candidates in just 10 months.
This technology-led approach not only accelerates the drug development timeline but also reduces costs and minimises risks, thereby enhancing the likelihood of introducing groundbreaking therapies to the market.
Poolbeg chief executive Jeremy Skillington said: "The positive outputs from this analysis, and the successful prioritisation of our RSV drug candidates, is a testament to the power of our AI-led drug discovery programme.
"As we engage in partnering discussions, these results position Poolbeg as a key player in the evolving landscape of AI-driven drug discovery."